ELVN
Enliven Therapeutics, Inc.
Price Chart
Latest Quote
$43.69
+2.20 (+5.30%)
Current Price
| Previous Close | $41.49 |
| Open | $41.80 |
| Day High | $44.34 |
| Day Low | $41.52 |
| Volume | 3,308,331 |
Stock Information
| Shares Outstanding | 73.27M |
| Total Debt | $1.51M |
| Cash Equivalents | $895.16M |
| Net Income | $-105.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.20B |
| EPS (TTM) | $-1.76 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.31B |
| Income | $-105.93M |
| Book/sh | $12.22 |
| Cash/sh | $12.22 |
| Employees | 67 |
Financial Ratios
| Quick Ratio | 63.21 |
| Current Ratio | 64.07 |
| Debt/Eq | 0.17 |
Returns & Margins
| ROA | -11.00% |
| ROE | -15.31% |
Ownership
| Insider Ownership | 6.22% |
| Institutional Ownership | 115.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -18.85 |
| P/B | 3.58 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $74.42 |
Technical Indicators
| SMA20 | $41.83 |
| SMA50 | $49.59 |
| SMA200 | $42.45 |
| RSI | 59.64 |
| ATR | 1.8191 |
| Shares Float | 60.52M |
| Short Float | 20.37% |
| Short Ratio | 7.20 |
| Volatility | 0.34 |
| Rel Volume | 2.10 |
Performance History
| Week | +5.92% |
| Month | -5.04% |
| Quarter | -17.52% |
| 6 Months | +1.65% |
| YTD | +181.15% |
| Year | +111.98% |
| 3 Years | +245.38% |
| 5 Years | +193.62% |
| 10 Years | -27.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $43.69 | 3,308,400 |
| 2026-10-26 | $41.49 | 2,323,100 |
| 2026-10-23 | $41.52 | 2,298,500 |
| 2026-10-22 | $41.93 | 2,324,900 |
| 2026-10-21 | $41.82 | 2,052,500 |
| 2026-10-20 | $41.25 | 1,938,200 |
| 2026-10-19 | $38.70 | 1,312,300 |
| 2026-10-16 | $37.32 | 1,188,400 |
| 2026-10-15 | $39.33 | 2,053,700 |
| 2026-10-14 | $39.28 | 1,217,100 |
| 2026-10-13 | $39.49 | 847,900 |
| 2026-10-12 | $40.84 | 579,800 |
| 2026-10-09 | $40.98 | 1,002,700 |
| 2026-10-08 | $40.63 | 1,651,600 |
| 2026-10-07 | $41.36 | 1,461,300 |
| 2026-10-06 | $42.39 | 2,333,000 |
| 2026-10-05 | $45.47 | 821,500 |
| 2026-10-02 | $46.97 | 1,123,200 |
| 2026-10-01 | $46.21 | 944,900 |
| 2026-09-30 | $45.84 | 800,200 |
| 2026-09-29 | $46.51 | 1,256,200 |
| 2026-09-28 | $46.01 | 1,284,600 |
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
đ° Latest News
No news articles available at the moment. Check back later for updates on ELVN.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $119,658,000 | $104,554,000 | $83,529,000 | $38,791,000 |
| Other Income Expense | $-49,000 | $871,000 | $-22,000 | - |
| Other Non Operating Income Expenses | $-49,000 | $-2,000 | $-22,000 | - |
| Net Non Operating Interest Income Expense | $16,013,000 | $14,891,000 | $11,967,000 | $1,129,000 |
| Operating Expense | $119,658,000 | $104,554,000 | $83,529,000 | $38,791,000 |
| General And Administrative Expense | $33,802,000 | $23,776,000 | $18,955,000 | $7,769,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Net Interest Income | $16,013,000 | $14,891,000 | $11,967,000 | $1,129,000 |
| Interest Income | $16,013,000 | $14,891,000 | $11,967,000 | $1,129,000 |
| Normalized Income | $-103,694,000 | $-89,713,670 | $-71,584,000 | $-37,662,000 |
| Net Income From Continuing And Discontinued Operation | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Total Operating Income As Reported | $-119,658,000 | $-104,554,000 | $-83,529,000 | $-38,791,000 |
| Net Income Common Stockholders | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Net Income | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Net Income Including Noncontrolling Interests | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Net Income Continuous Operations | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Pretax Income | $-103,694,000 | $-88,792,000 | $-71,584,000 | $-37,662,000 |
| Special Income Charges | $0 | $873,000 | $0 | - |
| Interest Income Non Operating | $16,013,000 | $14,891,000 | $11,967,000 | $1,129,000 |
| Operating Income | $-119,658,000 | $-104,554,000 | $-83,529,000 | $-38,791,000 |
| Per Share | ||||
| Diluted EPS | $-1.83 | $-1.89 | $-2.01 | $-0.92 |
| Basic EPS | $-1.83 | $-1.89 | $-2.01 | $-0.92 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $183,330 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-119,395,000 | $-105,110,000 | $-83,232,000 | $-38,576,000 |
| Total Unusual Items | $0 | $873,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $873,000 | $0 | - |
| Reconciled Depreciation | $263,000 | $317,000 | $297,000 | $215,000 |
| EBITDA (Bullshit earnings) | $-119,395,000 | $-104,237,000 | $-83,232,000 | $-38,576,000 |
| EBIT | $-119,658,000 | $-104,554,000 | $-83,529,000 | $-38,791,000 |
| Diluted Average Shares | $56,664,000 | $47,073,000 | $35,546,215 | $41,100,000 |
| Basic Average Shares | $56,664,000 | $47,073,000 | $35,546,215 | $41,100,000 |
| Diluted NI Availto Com Stockholders | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Tax Provision | $0 | $232,000 | $0 | - |
| Restructuring And Mergern Acquisition | $0 | $-873,000 | $0 | - |
| Research And Development | $85,856,000 | $80,778,000 | $64,574,000 | $31,022,000 |
| Selling General And Administration | $33,802,000 | $23,776,000 | $18,955,000 | $7,769,000 |
| Other Gand A | $33,802,000 | $23,776,000 | $18,955,000 | $7,769,000 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Total Assets | $476,168,000 | $325,760,000 | $271,867,000 | $83,298,000 |
| Total Non Current Assets | $1,290,000 | $7,633,000 | $5,716,000 | $5,545,000 |
| Other Non Current Assets | $656,000 | $7,175,000 | $4,091,000 | $54,000 |
| Non Current Deferred Assets | $217,000 | $0 | $563,000 | $3,975,000 |
| Current Assets | $474,878,000 | $318,127,000 | $266,151,000 | $77,753,000 |
| Other Current Assets | $12,257,000 | $4,633,000 | $12,949,000 | $2,217,000 |
| Restricted Cash | $0 | $54,000 | $54,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $462,621,000 | $313,440,000 | $253,148,000 | $75,536,000 |
| Cash And Cash Equivalents | $98,896,000 | $124,117,000 | $100,141,000 | $75,536,000 |
| Debt | ||||
| Total Debt | $399,000 | $0 | $335,000 | $323,000 |
| Current Debt And Capital Lease Obligation | $399,000 | - | $335,000 | $323,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $16,568,000 | $15,915,000 | $25,961,000 | $160,123,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $67,000 | $150,408,000 |
| Current Liabilities | $16,568,000 | $15,915,000 | $25,894,000 | $9,715,000 |
| Other Current Liabilities | $351,000 | $204,000 | $10,364,000 | $447,000 |
| Payables And Accrued Expenses | $11,523,000 | $11,102,000 | $11,867,000 | $6,815,000 |
| Payables | $2,159,000 | $1,342,000 | $532,000 | $3,438,000 |
| Accounts Payable | $2,159,000 | $1,342,000 | $532,000 | $3,438,000 |
| Other Non Current Liabilities | - | - | $67,000 | $659,000 |
| Equity | ||||
| Common Stock Equity | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Total Equity Gross Minority Interest | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Stockholders Equity | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Gains Losses Not Affecting Retained Earnings | $334,000 | $55,000 | $141,000 | $0 |
| Other Equity Adjustments | $334,000 | $55,000 | $141,000 | - |
| Retained Earnings | $-347,166,000 | $-243,472,000 | $-154,448,000 | $-82,864,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $149,749,000 |
| Other | ||||
| Ordinary Shares Number | $59,440,045 | $48,936,459 | $41,292,027 | $41,100,000 |
| Share Issued | $59,440,045 | $48,936,459 | $41,292,027 | $41,100,000 |
| Tangible Book Value | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Invested Capital | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Working Capital | $458,310,000 | $302,212,000 | $240,257,000 | $68,038,000 |
| Capital Lease Obligations | $399,000 | $0 | $335,000 | $323,000 |
| Total Capitalization | $459,600,000 | $309,845,000 | $245,906,000 | $-76,825,000 |
| Additional Paid In Capital | $806,373,000 | $553,213,000 | $400,172,000 | $6,038,000 |
| Capital Stock | $59,000 | $49,000 | $41,000 | $1,000 |
| Common Stock | $59,000 | $49,000 | $41,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $399,000 | $0 | $335,000 | $323,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,295,000 | $4,609,000 | $3,328,000 | $2,130,000 |
| Current Accrued Expenses | $9,364,000 | $9,760,000 | $11,335,000 | $3,377,000 |
| Net PPE | $417,000 | $458,000 | $1,062,000 | $1,516,000 |
| Accumulated Depreciation | $-229,000 | $-919,000 | $-671,000 | $-374,000 |
| Gross PPE | $646,000 | $1,377,000 | $1,733,000 | $1,890,000 |
| Other Properties | $383,000 | $1,113,000 | $1,511,000 | $1,817,000 |
| Machinery Furniture Equipment | $263,000 | $264,000 | $222,000 | $73,000 |
| Other Short Term Investments | $363,725,000 | $189,323,000 | $153,007,000 | $0 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-70,459,000 | $-73,236,000 | $-61,418,000 | $-32,689,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-70,301,000 | $-73,192,000 | $-61,269,000 | $-32,077,000 |
| Cash Flow From Continuing Operating Activities | $-70,301,000 | $-73,192,000 | $-61,269,000 | $-32,077,000 |
| Operating Gains Losses | $106,000 | $11,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-158,000 | $-44,000 | $-149,000 | $-612,000 |
| Investing Cash Flow | $-173,841,000 | $-35,997,000 | $-148,412,000 | $-612,000 |
| Cash Flow From Continuing Investing Activities | $-173,841,000 | $-35,997,000 | $-148,412,000 | $-612,000 |
| Net Other Investing Changes | - | $873,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $216,169,000 | $128,883,000 | $0 | - |
| Financing Cash Flow | $218,867,000 | $133,165,000 | $234,286,000 | $-1,799,000 |
| Cash Flow From Continuing Financing Activities | $218,867,000 | $133,165,000 | $234,286,000 | $-1,799,000 |
| Net Other Financing Charges | $-217,000 | - | $233,887,000 | $-2,390,000 |
| Net Common Stock Issuance | $216,169,000 | $128,883,000 | $0 | - |
| Common Stock Issuance | $216,169,000 | $128,883,000 | $0 | - |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $232,000 | $0 | - |
| End Cash Position | $98,896,000 | $124,171,000 | $100,195,000 | $75,590,000 |
| Beginning Cash Position | $124,171,000 | $100,195,000 | $75,590,000 | $110,078,000 |
| Changes In Cash | $-25,275,000 | $23,976,000 | $24,605,000 | $-34,488,000 |
| Proceeds From Stock Option Exercised | $2,915,000 | $4,282,000 | $399,000 | $591,000 |
| Net Investment Purchase And Sale | $-173,896,000 | $-36,826,000 | $-148,263,000 | $0 |
| Sale Of Investment | $272,898,000 | $313,914,000 | $120,000,000 | $0 |
| Purchase Of Investment | $-446,794,000 | $-350,740,000 | $-268,263,000 | $0 |
| Net PPE Purchase And Sale | $55,000 | $-44,000 | $-149,000 | $-612,000 |
| Sale Of PPE | $213,000 | $0 | - | - |
| Purchase Of PPE | $-158,000 | $-44,000 | $-149,000 | $-612,000 |
| Change In Working Capital | $-1,121,000 | $-4,541,000 | $1,401,000 | $438,000 |
| Change In Other Current Liabilities | $-337,000 | $-335,000 | $-310,000 | $4,000 |
| Change In Payables And Accrued Expense | $321,000 | $562,000 | $5,414,000 | $2,024,000 |
| Change In Accrued Expense | $-496,000 | $-248,000 | $7,664,000 | $1,613,000 |
| Change In Payable | $817,000 | $810,000 | $-2,250,000 | $411,000 |
| Change In Account Payable | $817,000 | $810,000 | $-2,250,000 | $411,000 |
| Change In Prepaid Assets | $-1,105,000 | $-4,768,000 | $-3,703,000 | $-1,590,000 |
| Other Non Cash Items | $353,000 | $-553,000 | $306,000 | - |
| Stock Based Compensation | $34,019,000 | $20,174,000 | $12,914,000 | $3,191,000 |
| Amortization Of Securities | $-227,000 | $424,000 | $-4,603,000 | $0 |
| Depreciation Amortization Depletion | $263,000 | $317,000 | $297,000 | $215,000 |
| Depreciation And Amortization | $263,000 | $317,000 | $297,000 | $215,000 |
| Depreciation | $263,000 | $317,000 | $297,000 | $215,000 |
| Gain Loss On Sale Of PPE | $106,000 | $11,000 | $0 | - |
| Net Income From Continuing Operations | $-103,694,000 | $-89,024,000 | $-71,584,000 | $-37,662,000 |
| Asset Impairment Charge | - | - | $0 | $1,741,000 |
| Preferred Stock Payments | - | - | - | - |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-10-26